Results of lamivudine trials in Asia (Q35621678)

9 August 2017

1 reference

title

Results of lamivudine trials in Asia (English)

1 reference

9 August 2017

1 reference

0 references

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S111-5

1 reference

Hepatitis B: global importance and need for control

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Natural history of hepatitis B virus infection in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Hepatitis B virus infection in Chinese families in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Chronic hepatitis B guidelines: east versus west

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900155-7

7 January 2021

10.1016/S0168-8278(03)00155-7

Identifiers

DOI

1 reference

9 August 2017

1 reference